ReviewMolecular brain2026
Bridging neurobiological mechanisms and translational applications in cognitive science: inspirations from the MCCS-NYUAD meeting 2025.
Review in Molecular brain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Molecular and Cellular Cognition Society (MCCS) Meeting (NYU Abu Dhabi, February 17-18th, 2025) brought together leading experts in neuroscience to present breakthroughs addressing the molecular and neuronal mechanisms underlying cognition, emotion, and behavior. This review is inspired by the meeting, which emphasized emerging molecular and cellular mechanisms including epigenetic regulation of memory, dynamic engram synapse formation, synaptic epitranscriptomics, metaplasticity, and metabolomic-neuroimmune interactions. Learning and cognition have increasingly become focal points within broader advances in neuroimaging innovations, high-throughput molecular diagnostics, and computational modeling geared toward precision neurodiagnostics and personalized neurocognitive therapeutics. The meeting also scrutinized how stress, circadian rhythm disruption, and neuroinflammation converge to shape cognitive resilience and dictate dysregulated attention and learning mechanisms underlying cognitive dysfunction. Such conditions span neurodevelopmental, neuropsychiatric, and neurodegenerative disorders. Collectively, the studies highlighted how experience-dependent synaptic and circuit-level changes influence cognition, sensory integration, and motor output. Further discussions addressed the translational implications of these findings, including their potential to advance neurotechnologies such as targeted neuromodulation, pharmacogenomic interventions, and AI-based biomarker discovery. Drawing on the scientific discussions at the MCCS-NYUAD meeting, we synthesize a research roadmap for the future of precision neurocognitive medicine by integrating molecular cognition with clinical neuroscience. Future research priorities include bridging gaps in molecular biomarkers of neurocognitive aging and leveraging AI-driven neurodiagnostics and large-scale biological data analytics. Overall, the meeting laid the groundwork for a shift in neuroscience toward linking mechanistic understanding with clinical relevance to enhance cognitive health and develop targeted neurotherapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.